Stockscreener 앱 받기
128.89
2.09%
-2.75
시간 외 거래:
128.89
전일 마감가:
$131.64
열려 있는:
$132.02
하루 거래량:
806.36K
Relative Volume:
0.71
시가총액:
$12.94B
수익:
$2.86B
순이익/손실:
$478.60M
주가수익비율:
27.61
EPS:
4.6676
순현금흐름:
$748.70M
1주 성능:
-2.06%
1개월 성능:
-0.75%
6개월 성능:
-5.66%
1년 성능:
+42.07%
1일 변동 폭
$127.17
$133.00
1주일 범위
$125.31
$134.20
52주 변동 폭
$88.35
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
128.89 | 13.21B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
18.08 | 58.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.86 | 50.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.84 | 44.61B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.82 | 36.05B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
571.73 | 25.19B | 3.18B | 1.33B | 1.04B | 27.90 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
(NBIX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc.M&A CallSlideshow (NASDAQ:NBIX) 2026-04-10 - Seeking Alpha
Volume Recap: Is Neurocrine Biosciences Inc forming a breakout patternEarnings Trend Report & Real-Time Market Trend Scan - baoquankhu1.vn
Neurocrine Biosciences Sees Significant Institutional Investment Boost - National Today
Rx Rundown: Gilead Sciences, Jeito Capital, Neurocrine Biosciences and more - Medical Marketing and Media
Morgan Stanley raises Neurocrine Bio price target on acquisition By Investing.com - Investing.com Canada
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
United StatesGoodwin Advises Centerview And Guggenheim On $2.9 Billion Sale Of Soleno Therapeutics To Neurocrine Biosciences - Mondaq
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock - ChartMill
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - TradingView
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio - Sahm
Momentum Shift: What hedge funds are buying Neurocrine Biosciences IncMarket Activity Recap & Verified Technical Trade Signals - baoquankhu1.vn
Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple - Yahoo Finance
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - The Economic Times
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $176 - Moomoo
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $242 - Moomoo
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story - Yahoo Finance
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology - The Chronicle-Journal
Neurocrine Biosciences (NASDAQ:NBIX) Given New $166.00 Price Target at Wedbush - MarketBeat
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²
RBC Capital Adjusts Neurocrine Biosciences PT to $176 From $177, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion | Vykat XRNews and Statistics - IndexBox
Robinhood Asset Management LLC Makes New $5.72 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to acquire Soleno in $2.9bn transaction - Pharmaceutical Technology
Neurocrine expands portfolio with buy of Soleno Therapeutics - The Pharma Letter
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition By Investing.com - Investing.com India
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition - Investing.com
Neurocrine to acquire Soleno in multi-billion dollar deal - marketscreener.com
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - Bitget
Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal - Yahoo Finance
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR - TechStock²
Neurocrine to seek Soleno (NASDAQ: SLNO) shares via tender offer - Stock Titan
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - axios.com
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - MedCity News
Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights
This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals
Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan
Wedbush raises Neurocrine Bio stock price target on acquisition By Investing.com - Investing.com India
Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - WHTC
Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen - Stocktwits
Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView
Oppenheimer raises Neurocrine Biosciences price target on acquisition By Investing.com - Investing.com Canada
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.31%
1.41%
자본화:
|
볼륨(24시간):